DE69939837D1 - Neue krebsbehandlung - Google Patents

Neue krebsbehandlung

Info

Publication number
DE69939837D1
DE69939837D1 DE69939837T DE69939837T DE69939837D1 DE 69939837 D1 DE69939837 D1 DE 69939837D1 DE 69939837 T DE69939837 T DE 69939837T DE 69939837 T DE69939837 T DE 69939837T DE 69939837 D1 DE69939837 D1 DE 69939837D1
Authority
DE
Germany
Prior art keywords
cell lines
prostate cancer
heterogeneity
cancer treatment
new cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69939837T
Other languages
German (de)
English (en)
Inventor
Angus George Dalgleish
Peter Michael Smith
Andrew Derek Sutton
Anthony Ian O Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Onyvax Ltd
Original Assignee
Onyvax Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onyvax Ltd filed Critical Onyvax Ltd
Application granted granted Critical
Publication of DE69939837D1 publication Critical patent/DE69939837D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
DE69939837T 1998-12-10 1999-12-09 Neue krebsbehandlung Expired - Lifetime DE69939837D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9827103.4A GB9827103D0 (en) 1998-12-10 1998-12-10 New cancer treatments
PCT/GB1999/004135 WO2000033870A2 (en) 1998-12-10 1999-12-09 New cancer treatments

Publications (1)

Publication Number Publication Date
DE69939837D1 true DE69939837D1 (de) 2008-12-11

Family

ID=10843925

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69939837T Expired - Lifetime DE69939837D1 (de) 1998-12-10 1999-12-09 Neue krebsbehandlung

Country Status (19)

Country Link
US (1) US6699483B1 (https=)
EP (1) EP1137434B1 (https=)
JP (1) JP4607330B2 (https=)
KR (1) KR100612552B1 (https=)
AT (1) ATE412425T1 (https=)
AU (1) AU777969B2 (https=)
CA (1) CA2354046C (https=)
CZ (1) CZ20012033A3 (https=)
DE (1) DE69939837D1 (https=)
ES (1) ES2315024T3 (https=)
GB (1) GB9827103D0 (https=)
HU (1) HUP0104857A3 (https=)
IL (2) IL143295A0 (https=)
MX (1) MXPA01005815A (https=)
NO (1) NO326035B1 (https=)
NZ (1) NZ512005A (https=)
PL (1) PL348829A1 (https=)
WO (1) WO2000033870A2 (https=)
ZA (1) ZA200104163B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60144515D1 (de) * 2000-04-01 2011-06-09 Onyvax Ltd Prostata zellinien und deren verwendung
AU2002232560A1 (en) 2000-10-27 2002-05-06 Immuno-Rx, Inc Vaccine immunotherapy for immune suppressed patients
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
CA2476999C (en) * 2002-02-22 2015-09-15 Intracel Resources Llc Sterile immunogenic non-tumorigenic tumor cell compositions and methods
US7176022B2 (en) * 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
US20050019336A1 (en) 2003-07-23 2005-01-27 Dalgleish Angus George Human prostate cell lines in cancer treatment
US20050180952A1 (en) * 2003-08-26 2005-08-18 Pettis Ronald J. Methods for intradermal delivery of therapeutics agents
EP2591786B1 (en) 2003-10-16 2017-04-12 Cancure Limited Immunomodulating compositions and uses therefor
US8257715B1 (en) * 2004-08-26 2012-09-04 University Of Notre Dame Tissue vaccines and uses thereof
US20090196850A1 (en) 2005-01-06 2009-08-06 Novo Nordisk A/S Anti-Kir Combination Treatments and Methods
US9308252B2 (en) * 2005-10-27 2016-04-12 Cook Biotech, Inc. Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
US8802113B2 (en) * 2005-10-27 2014-08-12 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US8778362B2 (en) 2005-10-27 2014-07-15 University Of Notre Dame Anti-tumor/cancer heterologous acellular collagenous preparations and uses thereof
US8778360B2 (en) * 2005-10-27 2014-07-15 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
GB0601598D0 (en) * 2006-01-26 2006-03-08 Stathopoulos Apostolos Method
US9283266B2 (en) * 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
US20110250218A1 (en) 2008-10-29 2011-10-13 Fong Lawrence H Disease-Associated Antigens and Methods of Use Thereof
CA3017298C (en) 2009-05-15 2021-09-28 Irx Therapeutics, Inc. Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
US8846059B2 (en) 2009-12-08 2014-09-30 University Of Notre Dame Extracellular matrix adjuvant and methods for prevention and/or inhibition of ovarian tumors and ovarian cancer
ES2667476T3 (es) 2009-12-08 2018-05-11 Irx Therapeutics, Inc. Método para invertir la supresión inmunitaria de células de Langerhans
US20110150934A1 (en) * 2009-12-18 2011-06-23 University Of Notre Dame Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer
CN105850982B (zh) * 2016-04-29 2018-08-17 绍兴市人民医院 一种新型组织冻存液
CN105850981B (zh) * 2016-04-29 2018-07-20 绍兴市人民医院 冻存肿瘤组织的方法
CN114729324A (zh) * 2019-07-24 2022-07-08 斯比根公司 永生化干细胞株的制备方法及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
JP2000502711A (ja) * 1995-12-28 2000-03-07 ザ ジョンズ ホプキンズ ユニヴァーシティ スクール オブ メディシン 同種異系パラクリンサイトカイン腫瘍ワクチン
WO1997028255A1 (en) * 1996-02-02 1997-08-07 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Immortal human prostate epithelial cell lines and clones and their applications in the research and therapy of prostate cancer
EP1125133A1 (en) * 1998-11-03 2001-08-22 Cell Genesys, Inc. Novel cancer-associated antigens and methods of their identification
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments

Also Published As

Publication number Publication date
KR20010090873A (ko) 2001-10-19
AU777969B2 (en) 2004-11-04
ZA200104163B (en) 2002-02-04
NO20012818L (no) 2001-06-07
CA2354046A1 (en) 2000-06-15
EP1137434B1 (en) 2008-10-29
JP2002531521A (ja) 2002-09-24
AU1668700A (en) 2000-06-26
IL143295A (en) 2006-04-10
WO2000033870A2 (en) 2000-06-15
KR100612552B1 (ko) 2006-08-11
NO326035B1 (no) 2008-09-01
HUP0104857A2 (hu) 2002-04-29
NZ512005A (en) 2004-01-30
ES2315024T3 (es) 2009-03-16
GB9827103D0 (en) 1999-02-03
MXPA01005815A (es) 2003-04-02
CZ20012033A3 (cs) 2001-10-17
CA2354046C (en) 2011-02-15
IL143295A0 (en) 2002-04-21
ATE412425T1 (de) 2008-11-15
WO2000033870A3 (en) 2000-08-17
PL348829A1 (en) 2002-06-17
NO20012818D0 (no) 2001-06-07
JP4607330B2 (ja) 2011-01-05
HUP0104857A3 (en) 2004-04-28
US6699483B1 (en) 2004-03-02
EP1137434A2 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
ATE412425T1 (de) Neue krebsbehandlung
JP2006525995A5 (https=)
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
MX2009009926A (es) Anticuerpo tumor-especifico humano monoclonal.
IL184617A0 (en) Dr5 antibodies and uses thereof
DK1556058T3 (da) Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi
DE69534946D1 (de) Verwendung von nackten Polynukleotiden zur Herstellung eines Medikaments für die Behandlung von Tumoren
PH12022551036A1 (en) Anti-mesothelin eribulin antibody-drug conjugates and methods of use
IL231810A (en) History of itensinoid and pharmaceutical preparations containing the same methods of preparation and use thereof for cancer treatment
WO2004112825A3 (en) Combinations of tumor-associated antigens for the treatment of various types of cancers
WO2003025138A3 (en) Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
BR112021025699A2 (pt) Anticorpos anti-mesotelina e imunoconjugados dos mesmos
WO2003097835A3 (en) Pharmaceutical compositions for the treatment of cancer
EA200970607A1 (ru) Универсальная вакцина из опухолевых клеток для противораковой терапии и профилактического использования
TW200612988A (en) Adjuvant therapy with the use of anti-glypican 3 antibody
EP1570081A4 (en) AMPLIFIED GENES INVOLVED IN CANCER
Naylor et al. Treatment of advanced melanoma with laser immunotherapy and ipilimumab
MX2018004556A (es) Metodo de mejora ex vivo de actividad de celula inmune para inmunoterapia del cancer con un compuesto ablativo de molecula pequeña.
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
Nikolsky Break in the cosmic ray spectrum or confinement violation near 10 6 TeV?
Schütz et al. Immunooncology in breast cancer: active and passive vaccination strategies
WO2006088464A3 (en) A method of using an anti-cd137 antibody as an agent for radioimmunotherapy or radioimmunodetection
DE69723580D1 (de) Impfstoff gegen metastasierenden kolorektalkrebs.
WO2000033871A3 (en) Use of human prostate tumour cell lines in cancer treatment
WO2004015063A3 (en) Amplification and overexpression of oncogenes

Legal Events

Date Code Title Description
8364 No opposition during term of opposition